Damora Therapeutics, Inc. (DMRA)
| Market Cap | 1.86B +47,073.3% |
| Revenue (ttm) | n/a |
| Net Income | -241.25M |
| EPS | -9.88 |
| Shares Out | 61.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,825 |
| Open | 27.49 |
| Previous Close | 28.00 |
| Day's Range | 27.39 - 30.35 |
| 52-Week Range | 2.45 - 38.33 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 44.67 (+48.6%) |
| Earnings Date | Aug 10, 2026 |
About DMRA
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for DMRA stock is "Strong Buy." The 12-month stock price target is $44.67, which is an increase of 48.60% from the latest price.
News
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today ...
Damora Therapeutics Quarterly report: Q2 2026
Damora Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Damora Therapeutics Earnings release: Q2 2026
Damora Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Damora Therapeutics Slides: Corporate presentation
Damora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical...
Damora Therapeutics price target raised to $40 from $35 at Wedbush
Wedbush raised the firm’s price target on Damora Therapeutics (DMRA) to $40 from $35 and keeps an Outperform rating on the shares. Relevant to Damora Therapeutics, Incyte (INCY) updated its…
Damora Therapeutics initiated with a Buy at Jefferies
Jefferies initiated coverage of Damora Therapeutics (DMRA) with a Buy rating and $50 price target. The company’s lead asset DMR-001 is a half-life extended anti-mutCALR monoclonal antibody, the analys...
Damora Therapeutics completes redomestication to the Cayman Islands
Damora Therapeutics (DMRA) announced the completion of the redomestication of the company from Delaware to the Cayman Islands, effective on July 16. The redomestication was previously approved by the ...
Damora Announces Redomestication from Delaware to Cayman Islands
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disor...
Damora Therapeutics Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, with all board recommendations approved by a strong quorum. Shareholders selected a one-year frequency for future compensation votes. Full voting results will be filed with the SEC.
Damora Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Damora Therapeutics (DMRA) with a Buy rating and $45 price target the company offers a “value opportunity” to own the biotech theme…
Wedbush bullish on Damora Therapeutics, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Damora Therapeutics (DMRA) with an Outperform rating and $35 price target. The firm views Damora as a compelling emerging hematology story centere...
Damora Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated coverage of Damora Therapeutics (DMRA) with an Outperform rating and $35 price target
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit fir...
Damora Therapeutics Slides: Corporate presentation
Damora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Damora Therapeutics Quarterly report: Q1 2026
Damora Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Damora Therapeutics Earnings release: Q1 2026
Damora Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Damora Therapeutics Proxy statement: Proxy filing
Damora Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Damora Therapeutics Proxy statement: Proxy filing
Damora Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Damora Therapeutics initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Damora Therapeutics (DMRA) with an Outperform rating and $40 price target The firm believes the company is “capitalizing on an increasingly validated approach” of usi...
Damora Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Damora Therapeutics (DMRA) with an Outperform rating and $46 price target
Damora names Peter Harwin chairman, appoints Spyre Therapeutics CEO to board
Damora Therapeutics (DMRA) also announced the appointment of Cameron Turtle, CEO of Spyre Therapeutics (SYRE) to the company’s board of directors. In addition, Peter Harwin, founding partner at Fairmo...
Damora Therapeutics appoints Jennifer Jarrett as CEO
Damora Therapeutics (DMRA) announced that its board of directors has appointed Jennifer Jarrett as president and CEO, effective March 30. Jarrett will also serve on the company’s board of directors.
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors --
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in ca...